China
China’s Akeso Completes Phase III Enrollment for Ivonescimab in Advanced Biliary Tract Cancer
Akeso (9926.HK) has recently announced the completion of patient enrollment in its Phase III, multicenter, randomized, controlled, registrational study eva...
September 03, 2025 | News
China’s Bon Natural Life Unveils Tea-Derived Compounds for Weight Management Through AI-Powered Drug Discovery
Bon Natural Life Limited , a leading bio-ingredient solution provider in the natural, health and personal care industry, announced a groundbreaking identif...
September 03, 2025 | News
Alphamab Oncology Reports Strong H1 2025 Growth and Pipeline Advancements, Achieving Profitability
Alphamab Oncology (stock code: 9966.HK) reported interim financial results for the six months ended June 30, 2025 and highlighted recent business...
September 01, 2025 | Company results
China’s WuXi Biologics Secures SBTi Approval for Net-Zero Targets, Reinforcing Global Green CRDMO Leadership
Committed to net-zero across the value chain by 2050 Aligned with 1.5°C mitigation pathways, the most ambitious SBTi designation Leader in Gre...
August 29, 2025 | News
China’s LakeShore Biopharma Receives Revised Take-Private Proposal from Oceanpine Capital-Led Consortium
LakeShore Biopharma Co., Ltd (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developin...
August 29, 2025 | News
China’s D3 Bio Secures FDA Breakthrough and Orphan Drug Designations for KRAS G12C Inhibitor D3S-001
Breakthrough Therapy Designation was granted for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cel...
August 29, 2025 | News
Cold Chain Technologies accelerates APAC expansion with new hubs, distributors, and manufacturing site
Cold Chain Technologies (CCT), has reinforced its commitment to expanding its Asia Pacific (APAC) presence with a series of investments and partnerships. ...
August 28, 2025 | News
Neusoft Medical Secures China’s First Approval For Photon-Counting CT With NeuViz P10
Neusoft Medical Systems announced that its NeuViz P10 photon-counting CT has received market approval from China's National Medical Product...
August 28, 2025 | News
Basecare Medical Secures NMPA Approval For VitBase Culture Medium Marking Breakthrough In China’s Assisted Reproductive Field
Suzhou Basecare Medical Co., Ltd. achieved a major breakthrough—its globally leading Gems culture medium (embryo handling solution VitBase) has offic...
August 27, 2025 | Regulatory
Leads Biolabs Doses First Patient In Phase II Trial Of LBL-034, China’s First Potential GPRC5D-Targeted T-Cell Engager
Nanjing Leads Biolabs Co., Ltd. announced the first patient has been successfully dosed in the Phase Ⅱ trial of LBL-034 (GPRC5D/CD3 BsAb) following...
August 26, 2025 | News
Antengene Reports Strong H1 2025 Results with Breakthrough Therapy Designation for ATG-022 and Robust Pipeline Progress
The Phase I/II CLINCH study of ATG-022 (CLDN18.2 antibody-drug conjugate) demonstrated promising results, showing robust clinical efficacy and a fav...
August 25, 2025 | Company results
China’s Bio-Thera and Europe’s STADA Expand Biosimilars Alliance to Include Tocilizumab
Bio-Thera and STADA agree to extend their biosimilars alliance to cover tocilizumab, a targeted immunomodulatory monoclonal antibody directed against the...
August 25, 2025 | News
BioDlink Secures Indonesian Approval for Bevacizumab, Accelerating ASEAN and Global Expansion
BioDlink announced that its Bevacizumab Injection has obtained marketing authorization from Indonesia's National Agency of Drug and Food Con...
August 22, 2025 | News
Asia-Pacific Leads the Charge: Latest Global BioSupplier Technologies of 2025
The first eight months of 2025 have been transformative for biosupplier technologies worldwide. From innovative lab reagents and biomaterials to ad...
August 22, 2025 | Analysis
Most Read
- The New AI Gold Rush: Western Pharma’s Billion-Dollar Bet on Chinese Biotech
- Top 25 Biotech & Biopharma Leaders in Sustainable Innovation, 2025
- China’s Biopharma Dealmaking Surges in H1 2025, Driven by Record Licensing and Oncology Focus
- Chikungunya in China: How a “Forgotten” Arbovirus Found the Perfect Storm
- How Innovation Gaps in Biopharma Raise New Safety Concerns
- Smart Implants and the Future of Musculoskeletal Injury Treatment
- How Ethical Gaps in Psychiatry Could Undermine Biopharma Progress
- The Evolving Landscape of Women’s Health Innovation in the Asia-Pacific
- Using NLP-Driven Decision Support in Emergency Health Assistance
- Taiwan Steps Into the Global Spotlight With a New Cancer Therapy
- The Role of Unique Device Identification (UDI) in Tracing Medical Device Safety
- The Importance of a Patient’s Mental Health During Clinical Trials
Bio Jobs
- The State of Biotech and Life Science Jobs in Asia Pacific – 2025
- Avantor’s New CEO Ligner Aims to Unlock Global Potential and Deliver Shareholder Value
- AstraZeneca Commits $50 Billion to U.S. Expansion by 2030 in Biggest-Ever Global Investment
- Thermo Fisher, SAMRC, and South Africa’s Department of Science and Innovation Launch CATIR to Nurture Next-Gen Scientists
- Cube Biotech Appoints Former Sartorius CEO Dr. Joachim Kreuzburg to Board of Directors
- FDA’s AI Transition Marks a Turning Point in Drug Review: Industry Faces Pressure to Adapt Amid 20% Workforce Cut
- WuXi XDC Completes Mechanical Build of Singapore Bioconjugate Manufacturing Hub
News
Editor Picks
